Biomea Fusion Inc BMEA 深 滬
等待開盤 04-02 09:30:00 美东时间
1.49
-0.040
-2.61%
華盛通- 最 高1.55
- 今 開1.53
- 成交量 131.33万股
- 最 低 1.46
- 昨 收 1.53
- 總市值 1.08亿
- 52周最高 3.08
- 市盈率 靜 --
- 換手率 1.82%
- 52周最低 0.8719
- 委 比 -43.52%
- 總股本 7229.94万
- 歷史最高 43.69
- 量 比 0.57
- 振 幅 5.88%
- 歷史最低 0.8719
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
Citigroup Maintains Buy on Biomea Fusion, Raises Price Target to $7
Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and raises the price target from $6 to $7.
03-27 23:12
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday...
03-20 20:05
美股夜盘 | AEye, Inc. Class A涨41.94%，Coffee控股涨13.88%
微宏控股涨-22.08%；Dragonfly Energy涨-20.89%；TaoWeave, Inc.涨-13.95%
03-17 08:11
Biomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients
Biomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients Biomea reported 52-week follow-up results from the Phase II COVALENT-111 trial of icovamenib in adults with type 2 diabetes at the ATTD conference. The double-blind, ran
03-14 16:30
Biomea Fusion to Present at Oppenheimer Healthcare Life Sciences Conference
Biomea Fusion to Present at Oppenheimer Healthcare Life Sciences Conference Biomea Fusion Inc. will present virtually at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 10:00 AM EDT, with an audio webcast available here: https://www.globenewswire.com/Tracker?
02-19 20:01
JPMorgan’s top short ideas for Q1: FTNT, TXT, IMO and more
J.P. Morgan’s U.S. equity thematic research team surveyed its top-ranked analysts to identify their most compelling structural and tactical short ideas heading into the first quarter of 2026. They fea...
01-24 00:24
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Biomea Fusion Expects To Enroll First Participant In COVALENT-211 Phase IIb Trial In Q1 2026, Provides Business Updates For This Year
Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or "the Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today outlined its execution priorities for 2026. The Company enters the year with strong
01-12 21:05
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
Biomea Fusion, a clinical-stage biopharmaceutical company, announced that its Interim CEO, Mick Hitchcock, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company will also host one-on-one meetings during the event. A live audio webcast of the presentation and its replay will be available through Biomea’s website. Biomea focuses on developing therapies for diabetes and obesity, targeting metabolic disord...
2025-12-17 12:00
